11 September 23: US FDA Grants Emergency Use Authorisation for ViraDx™
29 August 23: FY23 Full Year Results Presentation
29 August 23: FY23 Annual Report
16 August 23: Henry Schein Expands Distribution Partnership for FebriDx
16 August 23: Core Camera Reader Patent Granted in Europe and Japan
10 August 23: R&D Tax Rebate
3 August 23: Successful Capital Raise
27 July 23: Feasibility Project with Burnet Diagnostics Initiative
20 July 23: Quarterly Activity Statement and Cash Flow Report
18 July 23: Henry Schein Medical Expands Distribution
14 July 23: Change in Substantial Holding
14 July 23: Change in Substantial Holding
14 July 23: Notification of Cessation of Securities
14 July 23: Section 708A Cleansing Statement
14 July 23: Application for Quotation of Securities
14 July 23: Application for Quotation of Securities
13 July 23: Initial Director’s Interest Notice – DW
13 July 23: Doug Ward Appointed to Board
13 July 23: SPP – Cleansing Notice
13 July 23: Share Purchase Plan Offer Booklet
13 July 23: SPP – Letter to Eligible Shareholders
11 July 23: Application for Quotation of Securities – Amendment
11 July 23: Ceasing to Be a Substantial Holder from RYD
10 July 23: Proposed Issue of Securities
10 July 23: Lumos Completes $4.75m Placement and Launches SPP
10 July 23: Proposed Issue of Securities
07 July 23: Becoming a Substantial Holder
06 July 23: Change in Substantial Holding
06 July 23: Change in Substantial Holding
06 July 23: Trading Halt
06 July 23: Change in Substantial Holding
04 July 23: Application for Quotation of Securities
04 July 23: Application for Quotation of Securities
03 July 23: Lumos Receives US FDA Clearance for FebriDx
06 June 23: Application for Quotation of Securities
06 June 23: Change in Substantial Holding from RYD
06 June 23: Change in Substantial Holding
03 May 23: Application for Quotation of Securities
10 May 23: Change in Substantial Holding
10 May 23: Change in Substantial Holding
10 May 23: Notification Regarding Unquoted Securities
4 May 23: Application for Quotation of Securities
28 April 23: Change in Substantial Holding
28 April 23: Quarterly Activities/Appendix 4C Cash Flow Report
14 April 23: Change in Substantial Holding
4 April 23: Notification of Cessation of Securities
4 April 23: Application for Quotation of Securities
4 April 23: Application for Quotation of Securities
4 April 23: Change in Substantial Holding
30 March 23: Change in Substantial Holding
17 March 23: Application for Quotation of Securities
17 March 23: Lumos to Present at NWR Virtual Healthcare Conference
16 March 23: Lumos Signs Three New Agreements with Hologic
14 March 23: Application for Quotation of Securities
09 March 23: Change in Substantial Holding
06 March 23: Investor Presentation
02 March 23: Notification Regarding Unquoted Securities
02 March 23: Shareholder Webinar
27 February 23: FY23 First Half Year Results
27 February 23: Appendix 4D and Half Year Report
21 February 23: Change in Substantial Holding
21 February 23: Becoming a Substantial Holder
21 February 23: Change in Substantial Holding
20 February 23: Application for Quotation of Securities
9 February 23: Change in Substantial Holding
3 February 23: Change in Substantial Holding
30 January 23: Quarterly Activities/Appendix 4C Cash Flow Report
23 January 23: Change in Substantial Holding
16 January 23: Notification of Cessation of Securities
16 January 23: Notification Regarding Unquoted Securities
11 January 23: Change in Substantial Holding
11 January 23: Change in Substantial Holding
9 January 23: Application for Quotation of Securities
9 January 23: Notification Regarding Unquoted Securities
9 January 23: Cleansing Notice – Issue of Placement Shares
9 January 23: Cleansing Notice – Convertible Notes
22 December 22: Results of General Meeting
22 December 22: GM Chair Address
16 December 22: Notification Regarding Unquoted Securities – LDX
16 December 22: Change of General Meeting Format to Virtual Meeting
2 December 22: Change of Director’s Interest Notice – SL
2 December 22: Change of Director’s Interest Notice – BLG
2 December 22: Change of Director’s Interest Notice – CR
2 December 22: Cessation of Listed Options
2 December 22: Application for Quotation of Securities – LDX
2 December 22: Section 708A Cleansing Statement
2 December 22: New Constitution
1 December 22: Notification Regarding Unquoted Securities – LDX
30 November 22: Results of Annual General Meeting
30 November 22: AGM Chair Address & Presentation
29 November 22: Appendix 2A
23 November 22: Lumos Secures Two Service Agreements with Hologic
21 November 22: LDX Signs Agreement to Raise $8m and Announces General Meeting
28 October 22: Quarterly Activities – Cash Flow Report
19 October 22: Publication of Data from DISRUPT Clinical Trial in JAMA
03 October 22: Outcome of Appeal to FDA for FebriDx
26 August 22: Lumos Diagnostics FY22 Full Year Results
23 August 22: Lumos Pilot Manufacturing to Commence in Carlsbad
8 August 22: Lumos Files Appeal to the FDA for FebriDx
8 August 22: Lumos Withdraws from Local Manufacturing Proposal
2 August 22: Lumos to Close Sarasota Facility
29 July 22: Lumos Diagnostics’ Quarterly Activity Statement and Cash Flow Report
11 July 22: FDA Decision for FebriDx
06 July 22: Trading Halt
03 July 22: Change in Substantial Holding
02 July 22: Change in Substantial Holding
02 July 22: Change in Substantial Holding
01 July 22: Security Class Reinstatement of Quotation LDXO
30 June 22: Appendix 2A
30 June 22: Change of Director’s Interest Notice – BLG
30 June 22: Change of Director’s Interest Notice – CR
30 June 22: Change of Director’s Interest Notice – SL
28 June 22: Successful Completion of Retail Entitlement Offer
27 June 22: ViraDx Receives Interim Order Authorisation in Canada
24 June 22: Change in Substantial Holding
24 June 22: Security Class Suspension from Quotation LDXO
17 June 22: Lumos Secures Development Services Contract
16 June 22: Change in Substantial Holding
15 June 22: Shareholder Webinar
14 June 22: Change in Substantial Holding
14 June 22: Ceasing to be a Substantial Holder
13 June 22: Appendix 2A
10 June 22: Letter to Ineligible Shareholders
10 June 22: Letter to Eligible Shareholders
10 June 22: Retail Entitlement Offer Opens
8 June 22: Successful Completion of Institutional Entitlement Offer
6 June 22: Operational Update and Accelerate Entitlement Offer
6 June 22: Investor Presentation
6 June 22: Target Market Determination
6 June 22: Prospectus
6 June 22: Appendix 3B
29 April 22: Quarterly Activities/Appendix 4C Cash Flow Report
11 April 22: Operational Review & Management Reorganisation
5 April 22: Notification of Cessation of Securities
1 April 22: Notification Regarding Unquoted Securities
1 April 22: Notice of Cessation of Securities
14 Mar 22: Change in Substantial Holding
1 Mar 22: Change in Substantial Holding
28 Feb 22: FebriDx Update-Brazil Market Authorisation & New Study
28 Feb 22: FY2022 Half Year Update Presentation
28 Feb 22: Lumos Diagnostics FY2022 Half Year Results
28 Feb 22: Appendix 4D & Half Year Report
16 Feb 22: Appointment of Chief Financial Officer
11 Feb 22: Release of Shares from Escrow
11 Feb 22: Final Director’s Interested Notice
11 Feb 22: Change to Lumos Board
09 Feb 22: Application for Quotation of Securities
02 Feb 22: Victorian Government Intent for Lumos Manufacturing Hub
31 Jan 22: Change in Reporting Currency
31 Jan 22: Quarterly Activities/Appendix 4C Cash Flow Report
12 Jan 22: 100+ Pharmacies in Liverpool UK Launch FebriDx Service
24 Dec 21: Section 708A Cleansing Statement
24 Dec 21: Application for Quotation of Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Change in Substantial Holding
22 Dec 21: Lumos Completes ViraDx™ Development and Provides FebriDx® Regulatory Update
20 Dec 21: Ceasing to be a Substantial Holder
20 Dec 21: Lumos Diagnostics Receives Initial Orders for CoviDx in Canada
18 Nov 21: Release of Shares from Escrow
11 Nov 21: Investor Communication Channels
27 Oct 21: Monthly Activities & Appendix 4C Cash Flow Report
14 Oct 21: Notification of Cessation of Securities
8 Oct 21: Update on Economic Evaluation of FebriDx
6 Oct 21: Economic Evaluation of FebriDx
30 Sept 21: Notification Regarding Unquoted Securities
27 Sept 21: Proposed Issue of Securities
27 Sept 21: Notice of Annual General Meeting & Proxy Form
22 Sept 21: U.S. FDA Deprioritizes EUA Application for CoviDx
20 Sept 21: Notice of Change of Interests of Substantial Holder
14 Sept 21: Appointment of Dr. Jerome Adams as Strategic Health Adviser
1 Sept 21: Change in Substantial Holding
30 Aug 21: FY21 Annual Report
30 Aug 21: FY21 Full Year Results Investor Presentation
30 Aug 21: FY21 Full Year Results Media Release
30 Aug 21: Corporate Governance Statement
30 Aug 21: Appendix 4G
30 Aug 21: FY21 Appendix 4E
23 Aug 21: Release of Shares from Voluntary Escrow
13 Aug 21: FY21 Financial Results Release Date
3 Aug 21: Change in substantial holding – PV
2 Aug 21: Lumos Business Momentum Continues Following ASX Listing
13 Jul 21: Notification of cessation of securities – LDX
9 Jul 21: Becoming a substantial holder – EC
8 Jul 21: Investor Presentation
6 Jul 21: Becoming a substantial holder – ACL
5 Jul 21: Becoming a substantial holder – PV
2 Jul 21: Initial Director’s Interest Notice – BLG
2 Jul 21: Initial Director’s Interest Notice – CR
2 Jul 21: Initial Director’s Interest Notice – LM
2 Jul 21: Initial Director’s Interest Notice – RS
2 Jul 21: Initial Director’s Interest Notice – SL
1 Jul 21: Becoming a substantial holder
1 Jul 21: Becoming a substantial holder – PI
1 Jul 21: Becoming a substantial holder – RPS
1 Jul 21: Media Release – Lumos Diagnostics raises $63 million in ASX IPO
1 Jul 21: Pre-quotation Disclosures
1 Jul 21: Top 20 Holders
1 Jul 21: Distribution Schedule
1 Jul 21: Securities Trading Policy
1 Jul 21: Corporate Governance Statement
1 Jul 21: Long Term Incentive Plan Rules
1 Jul 21: Employee Share Option Plan Rules
1 Jul 21: Constitution
1 Jul 21: Prospectus
1 Jul 21: Appendix 1A and Information Form and Checklist
1 Jul 21: ASX Notice – Admission to Official List
Investor-related questions? Get in touch!
